2024
Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder
Corbera S, Wexler B, Bell M, Pittman B, Pelphrey K, Pearlson G, Assaf M. Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder. Schizophrenia Research 2024, 271: 1-8. PMID: 39002525, PMCID: PMC11384336, DOI: 10.1016/j.schres.2024.07.002.Peer-Reviewed Original ResearchAutism spectrum disorderPositive and Negative Syndrome ScaleAutism Diagnostic Observation Schedule-GenericExperiential negative symptomsPositive symptomsNegative symptomsExploratory factor analysisSpectrum disorderNegative Syndrome ScaleTarget negative symptomsSyndrome ScaleDiscriminant function analysisSZ relativesAssociated with quality of lifeSchizophreniaSocial skillsSocial functioningDiagnostic classificationAutismFactor analysisAssociated with qualityPredictor of diagnosisSymptomsDisordersQuality of lifeAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2020
O3.4. PSYCHOSIS PHENOTYPES FROM B-SNIP FOR CLINICAL ADVANCES: BIOTYPE CHARACTERISTICS AND TARGETS
Clementz B, Trotti R, Pearlson G, Keshavan M, Gershon E, Keedy S, Ivleva E, McDowell J, Tamminga C. O3.4. PSYCHOSIS PHENOTYPES FROM B-SNIP FOR CLINICAL ADVANCES: BIOTYPE CHARACTERISTICS AND TARGETS. Schizophrenia Bulletin 2020, 46: s7-s7. PMCID: PMC7234003, DOI: 10.1093/schbul/sbaa028.015.Peer-Reviewed Original ResearchClinical featuresPsychosis biotypesPsychosis casesPsychosis syndromeTreatment targetsSpecific treatment targetsB-SNIPClinical manifestationsBiomarker profilesPsychosis subgroupsB-SNIP consortiumDeep phenotyping approachPathophysiological mechanismsPsychosis patientsBipolar-Schizophrenia NetworkPsychosis diagnosisBiological subtypesHealthy personsClinical practiceClinical advancesNegative symptomsClinical phenomenologySyndrome
2019
O9.1. PROSPECTIVE MEMORY AND THE RELATIONSHIP TO SOCIAL FUNCTION AND NEGATIVE SYMPTOMS IN CLINICAL HIGH RISK, FIRST EPISODE PSYCHOSIS, AND SCHIZOPHRENIA
Teti A, Graham P, Fergione M, Haber L, Fiszdon J, Pearlson G, Choi J. O9.1. PROSPECTIVE MEMORY AND THE RELATIONSHIP TO SOCIAL FUNCTION AND NEGATIVE SYMPTOMS IN CLINICAL HIGH RISK, FIRST EPISODE PSYCHOSIS, AND SCHIZOPHRENIA. Schizophrenia Bulletin 2019, 45: s186-s187. PMCID: PMC6455356, DOI: 10.1093/schbul/sbz021.241.Peer-Reviewed Original Research
2017
5.3 Endophenotypes Guide Psychosis Neurobiology Formulations
Tamminga C, Clementz B, Keshavan M, Gershon E, Pearlson G, Ivleva E. 5.3 Endophenotypes Guide Psychosis Neurobiology Formulations. Schizophrenia Bulletin 2017, 43: s7-s7. DOI: 10.1093/schbul/sbx021.019.Peer-Reviewed Original ResearchConventional diagnosisFunctional brain biomarkersBiomarker compositesGray matter changesPsychosis researchHealthy controlsAdditional biomarkersClear pathophysiologyBrain biomarkersMatter changesAxis IProband groupsBiotype 1Higher negative symptomsLifetime ratesPsychiatric conditionsNegative symptomsPsychosis groupPsychotic conditionsSchizophrenia NetworkDistinct molecular markersDiagnosisAdolescent cannabisBiomarkersEEG characteristics
1985
Symptomatic, Familial, Perinatal, and Social Correlates of Computerized Axial Tomography (CAT) Changes in Schizophrenics and Bipolars
PEARLSON G, GARBACZ D, MOBERG P, AHN H, DEPAULO J. Symptomatic, Familial, Perinatal, and Social Correlates of Computerized Axial Tomography (CAT) Changes in Schizophrenics and Bipolars. The Journal Of Nervous And Mental Disease 1985, 173: 42-50. PMID: 3965611, DOI: 10.1097/00005053-198501000-00007.Peer-Reviewed Original ResearchConceptsVentricular enlargementFamily historyNegative symptomsComputerized axial tomography scanLateral ventricular enlargementAxial tomography scanPast psychiatric historyEarly brain damageMarked ventricular enlargementSubgroup of schizophrenicsPoor premorbid adjustmentLateral ventricularTomography changesBrain ratioPatient groupBrain damageTomography scanPsychiatric illnessPsychiatric historyBipolar patientsNormal controlsEarly onsetPatientsPremorbid adjustmentSignificant proportion
1984
Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder
Pearlson G, Garbacz D, Breakey W, Ahn H, DePaulo J. Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder. Psychiatry Research 1984, 12: 1-9. PMID: 6589656, DOI: 10.1016/0165-1781(84)90133-1.Peer-Reviewed Original Research